CUE
Cue Biopharma Inc
$
0.701
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.7432
Open
0.7039
VWAP
0.68
Vol
226.30K
Mkt Cap
53.88M
Low
0.6601
Amount
153.51K
EV/EBITDA(TTM)
--
Total Shares
48.64M
EV
27.95M
EV/OCF(TTM)
--
P/S(TTM)
6.25
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
1.88M
+345.37%
-0.095
-44.12%
1.70M
+7.7%
-0.095
-25.78%
2.29M
-31.36%
-0.085
-50.27%
Estimates Revision
The market is revising Downward the revenue expectations for Cue Biopharma, Inc. (CUE) for FY2025, with the revenue forecasts being adjusted by -12.16% over the past three months. During the same period, the stock price has changed by -15.62%.
Revenue Estimates for FY2025
Revise Downward
-12.16%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-7.78%
In Past 3 Month
Stock Price
Go Down
-15.62%
In Past 3 Month
1 Analyst Rating
Wall Street analysts forecast CUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CUE is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.701
Low
4.00
Averages
4.00
High
4.00
Current: 0.701
Low
4.00
Averages
4.00
High
4.00
Lucid Capital
Dev Prasad
Buy
initiated
$4
2025-08-25
Reason
Lucid Capital
Dev Prasad
Price Target
$4
2025-08-25
initiated
Buy
Reason
Lucid Capital analyst Dev Prasad initiated coverage of Cue Biopharma with a Buy rating and $4 price target. The company's lead asset CUE-401 is a novel bispecific for autoimmune disease, the analyst tells investors in a research note. The firm believes preclinical data show "strong mechanistic validation and broad efficacy" across autoimmune models.
Citizens Capital Markets
Reni Benjamin
Buy
Reiterates
$2
2025-04-02
Reason
Citizens Capital Markets
Reni Benjamin
Price Target
$2
2025-04-02
Reiterates
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Cue Biopharma Inc (CUE.O) is -1.90, compared to its 5-year average forward P/E of -3.72. For a more detailed relative valuation and DCF analysis to assess Cue Biopharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.72
Current PE
-1.90
Overvalued PE
-1.12
Undervalued PE
-6.33
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.74
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.95
Undervalued EV/EBITDA
-4.44
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
46.47
Current PS
0.70
Overvalued PS
103.92
Undervalued PS
-10.99
Financials
Annual
Quarterly
FY2025Q2
YoY :
+11.14%
2.95M
Total Revenue
FY2025Q2
YoY :
-16.84%
-8.64M
Operating Profit
FY2025Q2
YoY :
-16.61%
-8.48M
Net Income after Tax
FY2025Q2
YoY :
-55.00%
-0.09
EPS - Diluted
FY2025Q2
YoY :
-65.58%
-3.44M
Free Cash Flow
FY2025Q2
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q2
YoY :
-26.54%
-341.78
FCF Margin - %
FY2025Q2
YoY :
-24.96%
-287.14
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
30.9K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
30.9K
USD
Months
CUE News & Events
Events Timeline
2025-11-06 (ET)
2025-11-06
08:39:13
Cue Biopharma and ImmunoScape Forge Strategic Partnership and Licensing Agreement
2025-09-29 (ET)
2025-09-29
09:04:49
Cue Biopharma names Usman Azam as its new CEO
2025-08-13 (ET)
2025-08-13
08:16:01
Cue Biopharma announces initiation of investigator sponsored trial of CUE-102
Sign Up For More Events
Sign Up For More Events
News
9.5
11-08NASDAQ.COMCervoMed Inc. (CRVO) Announces Q3 Loss and Falls Short of Revenue Projections
9.5
11-07NASDAQ.COMPuma Biotech (PBYI) Exceeds Expectations with Q3 Earnings and Revenue
4.0
08-25BenzingaLUCID CAPITAL MARKETS Begins Coverage of Cue Biopharma with a Buy Rating and Sets Price Target at $4
Sign Up For More News
People Also Watch
IROQ
IF Bancorp Inc
25.815
USD
+0.06%
DGICB
Donegal Group Inc
15.950
USD
+4.59%
SPWH
Sportsmans Warehouse Holdings Inc
2.020
USD
-3.81%
ESP
Espey MFG & Electronics Corp
37.570
USD
+0.99%
AGEN
Agenus Inc
3.980
USD
+3.65%
VFF
Village Farms International Inc
2.960
USD
-0.34%
USAU
US Gold Corp
15.280
USD
+4.59%
JSPR
Jasper Therapeutics Inc
1.780
USD
-2.73%
TLSA
Tiziana Life Sciences Ltd
1.750
USD
-2.78%
FAQ
What is Cue Biopharma Inc (CUE) stock price today?
The current price of CUE is 0.7012 USD — it has decreased -2.1 % in the last trading day.
What is Cue Biopharma Inc (CUE)'s business?
What is the price predicton of CUE Stock?
What is Cue Biopharma Inc (CUE)'s revenue for the last quarter?
What is Cue Biopharma Inc (CUE)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Cue Biopharma Inc (CUE)'s fundamentals?
How many employees does Cue Biopharma Inc (CUE). have?